TRANSLATIONAL PHYSIOLOGY FXR silencing in human colon cancer by DNA methylation and KRAS signaling

Ann M. Bailey, Le Zhan, Dipen Maru, Imad Shureiqi, Curtis R. Pickering, Galina Kiriakova, Julie Izzo, Nan He, Caimiao Wei, Veerabhadran Baladandayuthapani, Han Liang, Scott Kopetz, Garth Powis, and Grace L. Guo Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Pharmacology, Toxicology, and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas; Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Sanford Burnham Medical Research Institute, Cancer Center, La Jolla, California; and Department of Pharmacology and Toxicology, School of Pharmacy, Rutgers University, Piscataway, New Jersey